OmniAb raises 2026 revenue and cash guidance on partner pipeline momentum

OmniAb reported second quarter 2026 results on August 6, 2026, alongside a series of updates from partner programs built on its antibody discovery technology.

Among the pipeline highlights, ramantamig (JNJ-79635322), a tri-specific antibody targeting BCMA, GPRC5D and CD3, advanced from Phase 1 to Phase 3, in a randomized study comparing it with an anti-BCMAxCD3 bispecific antibody in relapsed or refractory multiple myeloma patients who have already received at least three prior lines of therapy¹, as described in the trial's registry entry.

For Merck KGaA's precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, the first patient has been dosed in the Phase 3 PROCEADE-CRC-03 trial for metastatic colorectal cancer, based on Phase 1 data¹. In the earlier PROCEADE-CRC-01 study, at the recommended Phase 3 dose of 2.8 mg/kg every three weeks (n=29), the confirmed objective response rate was 20.7%, median progression-free survival was 6.9 months, and median overall survival had not been reached after a median follow-up of 13.1 months¹.

Teva plans to move its anti-IL-15 antibody TEV-'408 into a new stage: the company announced plans to advance TEV-'408 into a Phase 2b study in vitiligo in the fourth quarter of 2026, following encouraging Phase 1b results¹. In that Phase 1b trial, at week 24, nearly 75% of evaluable patients reported improvement in facial vitiligo, with 42% achieving F-VASI50 and 21% achieving F-VASI75¹. Separately, Teva and Royalty Pharma entered a funding agreement of up to $500 million to support TEV-'408's development for vitiligo¹.

Immunovant reported preliminary week 16 data for IMVT-1402: in a difficult-to-treat rheumatoid arthritis trial, response rates were 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70¹. The company said it expects to report topline data from a cutaneous lupus erythematosus trial in the second half of 2026, followed by Graves' disease and myasthenia gravis data in 2027 and chronic inflammatory demyelinating polyneuropathy and Sjögren's disease data in 2028¹.

On finances, OmniAb raised its 2026 revenue guidance to $32 million to $36 million from $28 million to $33 million previously, and now expects to end the year with cash and cash equivalents of $37 million to $41 million, up from $33 million to $38 million previously¹. As of June 30, 2026, the company had cash, cash equivalents and short-term investments of $52.0 million¹.